A study published in NEJM on December 11, 2024, led by Komal L. Jhaveri and colleagues, evaluated Imlunestrant, a next-generation oral selective estrogen receptor (ER) degrader, in ER-positive, HER2-negative advanced breast cancer.
Key Findings:
In patients with ESR1 mutations, Imlunestrant improved progression-free survival (PFS) to 5.5 months vs. 3.8 months with standard endocrine therapy (P<0.001).
The Imlunestrant-Abemaciclib combination resulted in 9.4 months PFS vs. 5.5 months with Imlunestrant alone (P<0.001).
Grade 3 or higher adverse events were observed in 17.1% (Imlunestrant), 20.7% (Standard Therapy), and 48.6% (Imlunestrant-Abemaciclib) groups.
Imlunestrant demonstrated a significant progression-free survival benefit in patients with ESR1 mutations but did not show a meaningful difference in the overall population. The combination of Imlunestrant with Abemaciclib significantly improved progression-free survival, irrespective of ESR1-mutation status, highlighting the potential of dual inhibition strategies in advanced breast cancer.
Thanks to Komal L. Jhaveri and the research team, including Patrick Neven, Monica Lis Casalnuovo, Sung-Bae Kim, Eriko Tokunaga, Philippe Aftimos, Cristina Saura, Joyce O’Shaughnessy, Nadia Harbeck, Lisa A. Carey, Giuseppe Curigliano, and others for their contributions.
For more details: https://lnkd.in/eFdq59SY
